Drug Profile
Research programme: galectin antagonists - iTeos Therapeutics
Alternative Names: Galectin 3 antagonist - iTeos TherapeuticsLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator iTeos Therapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Galectin 3 inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in Belgium (Parenteral)
- 15 Jan 2018 galectin antagonists programme is available for licensing as of 15 Jan 2018. http://www.iteostherapeutics.com/partnerships/objectives (iTeos Therapeutics pipeline, January 2018)
- 15 Jan 2018 Early research in Cancer in Belgium (Parenteral) before January 2018 (iTeos Therapeutics pipeline, January 2018)